Aspire Biopharma Holdings, Inc.

• Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems

• Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow profile

• Strategically diversifies Aspire's revenue streams

• Opportunity to drive significant shareholder value creation and enhance long-term capital allocation optionality

• Company does not anticipate procuring new equity financing to consummate the transaction

• Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS)

• LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase

Elite Ultra-Marathoner targets her second World Record in two months following historic

Interwest to Drive Regional Growth for BUZZ BOMB™ Across Major Grocery and Convenience Channels

Agreement Set to Expand BUZZ BOMB^™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels

Convenient Size at the Convenience Store

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.

Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026.

Alprazolam remains a top 40 prescribed medication in the US, with over 15.8 million prescriptions in 2023.

BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.

Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed

Aspire maintains listing on the Nasdaq

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine^®.

Meclizine was the top-prescribed antiemetic/antivertigo agent in 2023, with approximately 4.09 million prescriptions.

New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines

Ondansetron, currently sold under the brand name Zofran^®, was the 53rd most commonly prescribed medication in the U.S. in 2023

Global ondansetron market size valued at approximately $1.4 billion in 2023

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to full-scale GMP commercial manufacturing.

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial

• Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin

• Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication

• Presentation and 1x1 Investor Meetings Scheduled Across the Two-Day Virtual Conference

Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization

Future Platform Expansion into CNS, Men's Health, and Anti-Nausea

Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity

• SupraNaturals is a leading private label manufacturer in the health and wellness industry

• BUZZ BOMB™ pre-workout:

  • 50mg caffeine for energy and focus.

  • Boosts performance potential.

  • Stick packs:

    • Convenient, no water needed.

    • Precise caffeine dose

Global Market Insights: Pre-Workout Supplements

• Market Size in 2024: $19.6 billion

• Projected Market Size by 2030: $27.9 billion

• Compound Annual Growth Rate (CAGR): 5.9%

• Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing

• TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots

• This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage

• Lab results showed Aspire's product acted approximately twice as fast as the current recommendation for chewed aspirin tablet treatment

• These clinical trial results enable a potential regulatory submission for accelerated approval on track for Q3 2025

• First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience

Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO

Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market

• Early positive consumer testimonials from initial Company product sampling

• Sublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout market

• Developed through over a decade of scientific research to deliver a patent-pending, fast-acting supplement formulation for maximum effect

• Completed initial production in four flavors

• Aspire to launch BUZZ BOMB™ at the FITCON and Fit Expo conventions in August

Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025

Michael Howe - who currently serves as an Independent Board Member - to assume CEO role on June 10, 2025

Michael's career spans nationally recognized brands such as MinuteClinic, Procter & Gamble, PepsiCo, CEO of Arby's, and as an early-stage investor/board member in healthcare and software businesses

• Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market

• Initial production has commenced with six flavor options

• Expanded pre-launch consumer testing planned for Q2 2025

• Aspire to launch BUZZ BOMB™ at two major upcoming fitness conventions

• Marketing plan focused on cost-effective multi-channel digital strategy targeting primary influencers, direct response sales and traditional retail sales channels

• Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030

Trial marks key milestone in driving pipeline progress

Phase 1 trial scheduled for completion mid-June 2025

Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback

Company achieves another milestone relating to its clinical trial strategy